Skip to main content
Fig. 3 | BMC Complementary and Alternative Medicine

Fig. 3

From: A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia

Fig. 3

(a) Triglyceride level in amla extract and placebo group (p = 0.0003 between the groups); (b) Atherogenic index of plasma in amla extract and placebo group (p = 0.0177 between the groups); (c) Ratio of Apo B to Apo A1 at baseline and visit 5 in amla extract and placebo group (p = 0.0866 between the groups); (d) TC level at baseline and visit 5 in amla extract and placebo group (p = 0.0003 between the groups); (e) LDL-C level at baseline and visit 5 in amla extract and placebo group (p = 0.0064 between the groups); (f) CoQ10 level at baseline and visit 5 in amla extract and placebo group (p = 0.4581 between the groups)

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us